Revvity, Inc. (RVTY) EV/EBIT Ratio: 37.96x
Is Revvity, Inc.’s EV/EBIT ratio high or low?
Revvity, Inc.'s EV/EBIT ratio of 37.96x is 20% above its 5-year average of 31.68x, around the middle of its 5-year range (11.92x–50.30x).
As of Saturday, June 20, 2026. 6.57% above its 12-month average of 35.62x.
RVTY EV/EBIT Ratio Chart
RVTY Average EV/EBIT Ratio Chart
RVTY Current vs Average EV/EBIT Ratio Chart
RVTY EV/EBIT Ratio Metrics
EV/EBIT RATIO
37.96x
EV/EBIT RATIO AVG TTM
35.62x
EV/EBIT RATIO AVG 3Y
38.74x
EV/EBIT RATIO AVG 5Y
31.68x
EV/EBIT RATIO AVG 10Y
29.45x
EV/EBIT RATIO AVG 15Y
28.58x
EV/EBIT RATIO AVG 20Y
25.47x
CURRENT VS TTM AVG
+6.57%
CURRENT VS 3Y AVG
-2.01%
CURRENT VS 5Y AVG
+19.83%
CURRENT VS 10Y AVG
+28.88%
CURRENT VS 15Y AVG
+32.80%
CURRENT VS 20Y AVG
+49.05%
RVTY Competitors' EV/EBIT Ratio
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Revvity, Inc. (RVTY) | $11.16B | 37.96x | 35.62x | 38.74x | 31.68x |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | N/A | 25.59x | 34.39x | 25.01x |
| Baxter International Inc. (BAX)vs › | $10.27B | N/A | 442.63x | 243.35x | 134.31x |
| The Cooper Companies, Inc. (COO)vs › | $12.85B | 30.48x | 23.81x | 31.75x | 35.61x |
| Align Technology, Inc. (ALGN)vs › | $13.04B | 20.45x | 19.27x | 26.31x | 31.20x |
| Solventum Corporation (SOLV)vs › | $13.06B | 8.42x | 20.55x | 17.30x | 17.30x |
| Medpace Holdings, Inc. (MEDP)vs › | $13.14B | 22.74x | 28.22x | 28.07x | 28.06x |
| DaVita Inc. (DVA)vs › | $13.34B | 12.91x | 11.82x | 13.00x | 13.13x |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.91B | 25.15x | 62.10x | 38.56x | 35.07x |
| Tempus AI, Inc. (TEM)vs › | $8.87B | N/A | -27.13x | -28.45x | -29.28x |
Revvity, Inc. EV/EBIT Ratio Formula & Definition
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Revvity, Inc. EV/EBIT Ratio FAQ
- What is the EV/EBIT ratio for Revvity, Inc. (RVTY)?
- The EV/EBIT ratio for RVTY stock is 37.96x.
- Is Revvity, Inc.'s EV/EBIT ratio high or low?
- Revvity, Inc.'s EV/EBIT ratio of 37.96x is 20% above its 5-year average of 31.68x, around the middle of its 5-year range (11.92x–50.30x).
- What is the TTM average EV/EBIT ratio for Revvity, Inc. (RVTY)?
- The TTM average EV/EBIT ratio for RVTY stock is 35.62x.
- What is the 3Y average EV/EBIT ratio for Revvity, Inc. (RVTY)?
- The 3Y average EV/EBIT ratio for RVTY stock is 38.74x.
- What is the 5Y average EV/EBIT ratio for Revvity, Inc. (RVTY)?
- The 5Y average EV/EBIT ratio for RVTY stock is 31.68x.
- What is the 10Y average EV/EBIT ratio for Revvity, Inc. (RVTY)?
- The 10Y average EV/EBIT ratio for RVTY stock is 29.45x.
- What is the 15Y average EV/EBIT ratio for Revvity, Inc. (RVTY)?
- The 15Y average EV/EBIT ratio for RVTY stock is 28.58x.
- What is the 20Y average EV/EBIT ratio for Revvity, Inc. (RVTY)?
- The 20Y average EV/EBIT ratio for RVTY stock is 25.47x.
Revvity, Inc. EV/EBIT Ratio History
| DATE | EV/EBIT RATIO |
|---|---|
| 2026-06-18 | 37.96x |
| 2026-06-17 | 37.29x |
| 2026-06-16 | 38.34x |
| 2026-06-15 | 38.13x |
| 2026-06-12 | 37.86x |
| 2026-06-11 | 38.43x |
| 2026-06-10 | 38.36x |
| 2026-06-09 | 39.24x |
| 2026-06-08 | 38.06x |
| 2026-06-05 | 37.46x |
| 2026-06-04 | 38.71x |
| 2026-06-03 | 38.29x |
| 2026-06-02 | 38.08x |
| 2026-06-01 | 38.12x |
| 2026-05-29 | 39.38x |
| 2026-05-28 | 38.34x |
| 2026-05-27 | 36.97x |
| 2026-05-26 | 36.98x |
| 2026-05-22 | 37.02x |
| 2026-05-21 | 36.53x |
| 2026-05-20 | 36.35x |
| 2026-05-19 | 36.68x |
| 2026-05-18 | 36.56x |
| 2026-05-15 | 36.09x |
| 2026-05-14 | 36.84x |
| 2026-05-13 | 36.41x |
| 2026-05-12 | 37.74x |
| 2026-05-11 | 38.69x |
| 2026-05-08 | 39.34x |
| 2026-05-07 | 38.66x |
| 2026-05-06 | 38.74x |
| 2026-05-05 | 36.58x |
| 2026-05-04 | 34.74x |
| 2026-05-01 | 34.80x |
| 2026-04-30 | 34.78x |
| 2026-04-29 | 33.39x |
| 2026-04-28 | 34.32x |
| 2026-04-27 | 34.84x |
| 2026-04-24 | 34.83x |
| 2026-04-23 | 34.95x |
| 2026-04-22 | 37.21x |
| 2026-04-21 | 37.21x |
| 2026-04-20 | 36.81x |
| 2026-04-17 | 37.11x |
| 2026-04-16 | 35.70x |
| 2026-04-15 | 36.77x |
| 2026-04-14 | 36.97x |
| 2026-04-13 | 36.69x |
| 2026-04-10 | 35.78x |
| 2026-04-09 | 36.00x |
| 2026-04-08 | 35.98x |
| 2026-04-07 | 35.15x |
| 2026-04-06 | 35.32x |
| 2026-04-02 | 35.51x |
| 2026-04-01 | 35.19x |
| 2026-03-31 | 35.09x |
| 2026-03-30 | 34.19x |
| 2026-03-27 | 33.91x |
| 2026-03-26 | 34.94x |
| 2026-03-25 | 35.17x |
| 2026-03-24 | 35.04x |
| 2026-03-23 | 34.95x |
| 2026-03-20 | 34.56x |
| 2026-03-19 | 34.50x |
| 2026-03-18 | 34.24x |
| 2026-03-17 | 35.02x |
| 2026-03-16 | 34.73x |
| 2026-03-13 | 34.44x |
| 2026-03-12 | 34.19x |
| 2026-03-11 | 35.73x |
| 2026-03-10 | 35.95x |
| 2026-03-09 | 36.52x |
| 2026-03-06 | 36.28x |
| 2026-03-05 | 37.94x |
| 2026-03-04 | 38.55x |
| 2026-03-03 | 37.74x |
| 2026-03-02 | 37.63x |
| 2026-02-27 | 38.49x |
| 2026-02-26 | 38.71x |
| 2026-02-25 | 38.25x |
| 2026-02-24 | 38.27x |
| 2026-02-23 | 36.78x |
| 2026-02-20 | 37.78x |
| 2026-02-19 | 37.65x |
| 2026-02-18 | 36.97x |
| 2026-02-17 | 36.13x |
| 2026-02-13 | 36.44x |
| 2026-02-12 | 36.30x |
| 2026-02-11 | 38.02x |
| 2026-02-10 | 39.16x |
| 2026-02-09 | 38.56x |
| 2026-02-06 | 38.17x |
| 2026-02-05 | 37.53x |
| 2026-02-04 | 38.87x |
| 2026-02-03 | 38.03x |
| 2026-02-02 | 39.89x |
| 2026-01-30 | 40.42x |
| 2026-01-29 | 40.33x |
| 2026-01-28 | 41.15x |
| 2026-01-27 | 42.24x |
| 2026-01-26 | 42.27x |
| 2026-01-23 | 42.90x |
| 2026-01-22 | 43.22x |
| 2026-01-21 | 42.84x |
| 2026-01-20 | 41.39x |
| 2026-01-16 | 41.58x |
| 2026-01-15 | 42.46x |
| 2026-01-14 | 41.27x |
| 2026-01-13 | 40.84x |
| 2026-01-12 | 38.89x |
| 2026-01-09 | 39.06x |
| 2026-01-08 | 38.21x |
| 2026-01-07 | 38.61x |
| 2026-01-06 | 39.25x |
| 2026-01-05 | 38.32x |
| 2026-01-02 | 37.10x |
| 2025-12-31 | 36.66x |
| 2025-12-30 | 36.88x |
| 2025-12-29 | 36.78x |
| 2025-12-26 | 36.66x |
| 2025-12-24 | 36.67x |
| 2025-12-23 | 36.92x |
| 2025-12-22 | 36.98x |
| 2025-12-19 | 36.50x |
| 2025-12-18 | 36.51x |
| 2025-12-17 | 36.67x |
| 2025-12-16 | 36.51x |
| 2025-12-15 | 37.39x |
| 2025-12-12 | 37.83x |
| 2025-12-11 | 38.90x |
| 2025-12-10 | 38.77x |
| 2025-12-09 | 37.30x |
| 2025-12-08 | 37.61x |
| 2025-12-05 | 37.92x |
| 2025-12-04 | 38.47x |
| 2025-12-03 | 38.70x |
| 2025-12-02 | 38.53x |
| 2025-12-01 | 38.44x |
| 2025-11-28 | 39.05x |
| 2025-11-26 | 39.13x |
| 2025-11-25 | 39.42x |
| 2025-11-24 | 37.86x |
| 2025-11-21 | 37.14x |
| 2025-11-20 | 35.81x |
| 2025-11-19 | 35.26x |
| 2025-11-18 | 35.51x |
| 2025-11-17 | 34.89x |
| 2025-11-14 | 35.41x |
| 2025-11-13 | 35.62x |
| 2025-11-12 | 35.85x |
| 2025-11-11 | 35.90x |
| 2025-11-10 | 35.27x |
| 2025-11-07 | 34.80x |
| 2025-11-06 | 34.41x |
| 2025-11-05 | 35.36x |
| 2025-11-04 | 35.08x |
| 2025-11-03 | 33.45x |
| 2025-10-31 | 33.64x |
| 2025-10-30 | 32.88x |
| 2025-10-29 | 34.14x |
| 2025-10-28 | 34.48x |
| 2025-10-27 | 34.69x |
| 2025-10-24 | 35.20x |
| 2025-10-23 | 34.81x |
| 2025-10-22 | 34.25x |
| 2025-10-21 | 34.61x |
| 2025-10-20 | 34.15x |
| 2025-10-17 | 33.59x |
| 2025-10-16 | 33.76x |
| 2025-10-15 | 33.20x |
| 2025-10-14 | 32.91x |
| 2025-10-13 | 32.87x |
| 2025-10-10 | 32.07x |
| 2025-10-09 | 33.07x |
| 2025-10-08 | 33.10x |
| 2025-10-07 | 32.93x |
| 2025-10-06 | 33.57x |
| 2025-10-03 | 33.77x |
| 2025-10-02 | 33.01x |
| 2025-10-01 | 33.10x |
| 2025-09-30 | 31.88x |
| 2025-09-29 | 30.86x |
| 2025-09-26 | 30.82x |
| 2025-09-25 | 30.52x |
| 2025-09-24 | 30.95x |
| 2025-09-23 | 31.31x |
| 2025-09-22 | 31.47x |
| 2025-09-19 | 31.61x |
| 2025-09-18 | 31.91x |
| 2025-09-17 | 31.21x |
| 2025-09-16 | 31.18x |
| 2025-09-15 | 30.80x |
| 2025-09-12 | 30.47x |
| 2025-09-11 | 31.30x |
| 2025-09-10 | 30.36x |
| 2025-09-09 | 31.11x |
| 2025-09-08 | 31.48x |
| 2025-09-05 | 31.58x |
| 2025-09-04 | 31.31x |
| 2025-09-03 | 30.61x |
| 2025-09-02 | 31.95x |
| 2025-08-29 | 32.61x |
| 2025-08-28 | 32.35x |
| 2025-08-27 | 32.16x |
| 2025-08-26 | 32.94x |
| 2025-08-25 | 33.21x |
| 2025-08-22 | 33.80x |
| 2025-08-21 | 32.48x |
| 2025-08-20 | 33.08x |
| 2025-08-19 | 33.00x |
| 2025-08-18 | 32.48x |
| 2025-08-15 | 32.81x |
| 2025-08-14 | 32.41x |
| 2025-08-13 | 32.85x |
| 2025-08-12 | 31.99x |
| 2025-08-11 | 31.34x |
| 2025-08-08 | 31.64x |
| 2025-08-07 | 31.53x |
| 2025-08-06 | 31.37x |
| 2025-08-05 | 32.19x |
| 2025-08-04 | 31.34x |
| 2025-08-01 | 31.31x |
| 2025-07-31 | 31.22x |
| 2025-07-30 | 32.08x |
| 2025-07-29 | 33.15x |
| 2025-07-28 | 33.32x |
| 2025-07-25 | 35.86x |
| 2025-07-24 | 35.36x |
| 2025-07-23 | 34.61x |
| 2025-07-22 | 33.64x |
| 2025-07-21 | 32.05x |
| 2025-07-18 | 32.79x |
| 2025-07-17 | 33.48x |
| 2025-07-16 | 33.28x |
| 2025-07-15 | 33.57x |
| 2025-07-14 | 34.33x |
| 2025-07-11 | 35.22x |
| 2025-07-10 | 35.48x |
| 2025-07-09 | 34.81x |
| 2025-07-08 | 34.97x |
| 2025-07-07 | 34.40x |
| 2025-07-03 | 35.16x |
| 2025-07-02 | 35.04x |
| 2025-07-01 | 34.49x |
| 2025-06-30 | 33.81x |
| 2025-06-27 | 34.13x |
| 2025-06-26 | 34.42x |
| 2025-06-25 | 34.10x |
| 2025-06-24 | 33.71x |
| 2025-06-23 | 33.29x |
| 2025-06-20 | 33.30x |
| 2025-06-18 | 33.13x |
| 2025-06-17 | 33.06x |
| 2025-06-16 | 33.70x |
| 2025-06-13 | 32.87x |
| 2025-06-12 | 33.51x |
| 2025-06-11 | 33.62x |
| 2025-06-10 | 33.67x |
| 2025-06-09 | 32.68x |
| 2025-06-06 | 32.41x |
Showing the most recent 260 of 4,970 data points. The chart above shows the full history.
Related Metrics
About Revvity, Inc.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Prahlad R. Singh